Biguanides (i.e., N=c(-n)-n(n-)c=n) Patents (Class 514/635)
  • Patent number: 11103451
    Abstract: The present invention provides a method of treatment of inflammatory disorder of the eye, said method comprising administering into the eye of a person in need thereof, an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02% to 0.04% weight by volume in an aqueous vehicle, wherein the solution is free of oil and wherein the solution is administered twice-a-day. The present invention also provides an ophthalmic solution comprising a. therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii. polyethoxylated castor oil, b. in an aqueous vehicle. wherein the crystal growth inhibitor is polyvinyl alcohol or its derivatives.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: August 31, 2021
    Assignee: Sun Pharma Advanced Research Company Limited
    Inventors: Ajay Jaysingh Khopade, Arindam Halder, Ankit Shaileshkumar Shah
  • Patent number: 11028349
    Abstract: Described herein, are personal care compositions comprising an effective amount of an antibacterial component selected from chloroxylenol (PCMX) and o-cymene-5-on (IPMP); phenoxyethanol; piroctone olamine; and a surfactant. Methods of making and using these compositions are also described.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 8, 2021
    Assignee: Colgate-Palmolive Company
    Inventors: Yang Ruan, Huiyan Yin, Eugene Hardy
  • Patent number: 11000475
    Abstract: The present invention provides an ophthalmic solution comprising a. therapeutically effective concentration of difluprednate, a crystal growth inhibitor and pharmaceutically acceptable amounts of a solubilizer comprising a mixture of i. quaternary ammonium compound and ii. polyethoxylated castor oil, b. in an aqueous vehicle. wherein the crystal growth inhibitor is polyvinyl alcohol or its derivatives. Also, the present invention provides a method of treatment of inflammatory disorder of the eye, said method comprising administering into the eye of a person in need thereof, an aqueous solution comprising difluprednate as the sole active ingredient at a concentration of 0.02% to 0.04% weight by volume in an aqueous vehicle, wherein the solution is free of oil and wherein the solution is administered twice-a-day.
    Type: Grant
    Filed: October 15, 2016
    Date of Patent: May 11, 2021
    Assignee: Sun Pharma Advanced Research Company Limited
    Inventors: Ajay Jaysingh Khopade, Arindam Halder, Ankit Shaileshkumar Shah
  • Patent number: 10920174
    Abstract: Anti-microbial compositions for cleaning and sanitizing skin are disclosed. The anti-microbial compositions preferably comprises at least one quaternary ammonium chloride active and results in low irritation cleansing and sanitizing products that allow more frequent application.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: February 16, 2021
    Assignee: GPCP IP Holdings LLC
    Inventors: Brian Patrick Argo, Varsha Shah, Molly Ryan Callahan
  • Patent number: 10512667
    Abstract: Provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production. In particular, provided herein are methods for treating subjects having conditions related to adrenocortical activity and/or excessive steroid production through administration of at least one of the following agents: 1) an agent capable of inhibiting cholesterol efflux related to ABCA1 and/or ABCG1; 2) an agent capable of inhibiting MDR1 related cortisol secretion and/or MDR1 P-glycoprotein multiple drug transporter activity; and 3) an agent capable of inhibiting mitochondrial activity.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: December 24, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tom K. Kerppola, Veronica E. Burns
  • Patent number: 10226437
    Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: March 12, 2019
    Assignee: INNOVATION TECHNOLOGIES, INC.
    Inventors: Carolyn L. Twomey, Gareth Clarke, Samuel J. Zaidspiner
  • Patent number: 10016375
    Abstract: The subject invention provides materials and methods for reducing ocular infections in subjects. The materials and methods utilize chlorhexidine, which has been found to be unexpectedly non-toxic to humans and other animals in low concentrations. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought possible.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: July 10, 2018
    Inventor: Paul J. Rucinski
  • Patent number: 9968594
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. In a preferred embodiment correction of presbyopia occurs without reduction in distance vision acuity. The compositions of the invention preferably contain a muscarinic agonist and a cycloplegic agent.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: May 15, 2018
    Assignee: Presbyopia Therapies LLC
    Inventors: Gerald Horn, Lee Nordan
  • Patent number: 9913816
    Abstract: A method for using metformin and sodium butyrate in combination to treat a cancer patient with K-ras mutation is disclosed. When administering the pharmaceutical composition to a cancer patient, Metformin and sodium butyrate offer cooperatively therapeutic efficacy. The present invention also discloses a pharmaceutical composition and a pharmaceutical kit containing both aforementioned. The application of the method, the pharmaceutical composition and the pharmaceutical kit of the present invention are advantageous for improving the treatment effect to cancer patients with K-ras mutation.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: March 13, 2018
    Inventors: Kwan-Hwa Chi, Yu-Shan Wang, Chao-Chun Chang
  • Patent number: 9833441
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a cycloplegic agent. The compositions optionally contain a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: December 5, 2017
    Assignee: Presbyopia Therapies LLC
    Inventors: Gerald Horn, Lee Nordan
  • Patent number: 9808440
    Abstract: Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: November 7, 2017
    Assignee: RESEARCH INSTITUTE FOR NUTRITION AND AGING CO., LTD.
    Inventors: Kunihiko Kiyono, Kenji Onishi, Yasuharu Nagahama, Takashi Watanabe
  • Patent number: 9668989
    Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: June 6, 2017
    Assignee: INNOVATION TECHNOLOGIES, INC.
    Inventors: Carolyn L. Twomey, Gareth Clarke, Samuel J. Zaidspiner
  • Patent number: 9233085
    Abstract: A topical composition containing an adenosine monophosphate protein kinase (AMPK) activator and methods of administering the AMPK activator for treating acute pain or preventing the development of chronic pain in a subject. The AMPK activator is resveratrol. A second AMPK activator may also be used. The second AMPK activator is metformin. The topical composition may be administered as a gel, ointment, cream, lotion, suspension, liquid, or transdermal patch.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 12, 2016
    Assignee: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Theodore J. Price, Gregory D. Dussor, Dipti Tillu, Bo Lian
  • Patent number: 9174931
    Abstract: The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
    Type: Grant
    Filed: December 25, 2014
    Date of Patent: November 3, 2015
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Publication number: 20150147282
    Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: November 24, 2014
    Publication date: May 28, 2015
    Inventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
  • Publication number: 20150118283
    Abstract: The invention relates to a wound dressing which is particularly suitable for therapeutically dressing wounds. Said wound dressing comprises at least one wound covering layer and at least one sorbent based on an activated carbon which has a biocidal and/or biostatic, in particular antimicrobial effect and/or finish.
    Type: Application
    Filed: August 31, 2012
    Publication date: April 30, 2015
    Inventors: Hasso Von Blücher, Raik Schönfeld, Frank Pallaske
  • Publication number: 20150118275
    Abstract: The present invention relates to methods and compositions for rendering a surface resistant to bio-film formation by a combination of an alkanediol and an antimicrobial agent (and, optionally, an organic hydroxy acid). The invention provides for compositions which may be used to render surfaces bio-film resistant, articles having bio-film resistant surfaces, and methods for their preparation. The present invention may be advantageously applied to medical articles as well as articles used in non-medical contexts, such as child care or food preparation.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 30, 2015
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Shanta Modak, Arnab Kumar Ghosh, Ronald Citron, Santoshkumar Hanmantrao Dongre, Nayana Baiju
  • Publication number: 20150110881
    Abstract: A pharmaceutical composition for use in oral medication for the treatment of diabetes mellitus can include an antacid agent with an enteric coating, which permits the antacid agent to be delivered in the small intestine where it reduces acidity thereby causing a lowering of blood sugar levels. The pharmaceutical composition can be packaged in various tablet forms, including standard tablets and multiple pellet tablets. The pharmaceutical composition can further include a composition for treatment of diabetes, such as metformin, in enteric or non-enteric formulations. The pharmaceutical composition can further include an enteric-coated gastric acid secretion inhibitor. Also disclosed are methods for the treatment of diabetes mellitus, using the pharmaceutical composition and its variants.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 23, 2015
    Inventors: Kenneth John Tibbs, Dawn Ann Tibbs
  • Publication number: 20150110843
    Abstract: Fibrous antimicrobial materials for use in structures and barrier applications, such as face masks and wound dressings, have been developed from antimicrobial polymeric materials. The fibrous antimicrobial materials also are particularly suitable for use in air and water filtration. The antimicrobial polymeric materials are prepared from solid solutions of antimicrobial bisguanide compounds blended with certain thermoplastic polymers. The antimicrobial polymeric materials may be extruded into fibers or used in the particulate form for preparation of the nonwoven antimicrobial materials. The antimicrobial bisguanide compound, such as chlorhexidine, are distributed at the molecular level within at least one thermoplastic polymer, such as a polyolefin in which the antimicrobial bisguanide compound is soluble, to form a miscible blend. Methods for their formation and use also are provided.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Jan W. Gooch, Thomas J. Steimer, SR.
  • Publication number: 20150105472
    Abstract: The invention relates to an antimicrobial composition comprising chlorhexidine and pentane-1,5-diol. Such a composition may be used to combat microorganisms.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 16, 2015
    Inventor: Jan FAERGEMANN
  • Patent number: 9005637
    Abstract: Compositions and methods for combination therapy are provided. The compositions comprise a multiple unit dosage form having both a therapeutic agent and a nutritional supplement. The combination therapy is useful for restoring a nutrient depletion associated with a particular disease state. Additionally, the combination therapy can prevent or attenuate the depletion of a nutrient caused, in whole or in part, by the co-administrated therapeutic drug. Methods of manufacturing the formulations are likewise described.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: April 14, 2015
    Assignee: JDS Therapeutics, LLC
    Inventor: James R Komorowski
  • Publication number: 20150094368
    Abstract: Methods of delaying the onset of an infection or preventing an infection caused by a microbial organism in an internal cavity of a subject are provided. Methods of killing or inactivating microorganisms in at least a portion of the urethra of a subject are provided.
    Type: Application
    Filed: December 1, 2014
    Publication date: April 2, 2015
    Inventors: Matthew T. Scholz, Terry R. Hobbs, DanLi Wang
  • Patent number: 8993633
    Abstract: It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The present disclosure relates to therapeutic agents, compositions and methods for treating a muscle disease or condition characterized by impaired insulin-dependent signaling by targeting components of the defective insulin signaling pathway. The disease or condition may be treated by administering a therapeutic agent that activates the insulin signaling pathway, in particular, therapeutic agents that act post-insulin receptor to modulate intracellular effector molecules. An exemplary modulator is metformin. Metformin may be administered alone or may be coadministered with another therapeutic agent for treating the muscle disease or condition, such as a corticosteroid.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: March 31, 2015
    Assignees: Fate Therapeutics, (Canada) Inc., Ottaw Hospital Research Institute
    Inventors: Lynn Megeney, Carol Evans
  • Publication number: 20150087717
    Abstract: The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. These formulations have a high cidal activity in a short amount of time and provide stable copious foam. The formulations of the present invention also exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.
    Type: Application
    Filed: December 5, 2014
    Publication date: March 26, 2015
    Inventors: Daniel E. Pedersen, Angela R. Eder, Charles Allen Hodge
  • Publication number: 20150087716
    Abstract: The present disclosure invention relates to medical devices treated with a solution comprising one or more solvents and a combination of chlorhexidine free base and a water-soluble chlorhexidine salt in a weight/weight ratio of between about 1:1 to about 1:5, preferably about 1:1.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Shanta M. Modak, Lester A. Sampath
  • Publication number: 20150087642
    Abstract: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 26, 2015
    Inventors: Bronislava GEDULIN, Andrew A. YOUNG, Howard E. GREENE
  • Publication number: 20150080296
    Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a protein digestibility corrected amino acid score (PDCAAS) that exceeds a benchmark protein. Also provided are nucleic acids encoding the proteins, recombinant microorganisms that make the proteins, methods of making the proteins using recombinant microorganisms, compositions that comprise the proteins, and methods of using the proteins, among other things.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 19, 2015
    Inventors: Nathaniel W. Silver, Geoffrey von Maltzahn, Michael J. Hamill, David Arthur Berry
  • Publication number: 20150073057
    Abstract: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of metformin to the colon by bypassing the upper digestive tract.
    Type: Application
    Filed: September 6, 2013
    Publication date: March 12, 2015
    Applicant: BioKier, Inc.
    Inventor: Jerzy Ryszard Szewczyk
  • Publication number: 20150064118
    Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.
    Type: Application
    Filed: September 15, 2014
    Publication date: March 5, 2015
    Inventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
  • Publication number: 20150065578
    Abstract: Methods for improving the gastrointestinal tolerability of biguanide compounds and for treating metabolic disorders and/or inducing weight loss in patients in need thereof, particularly in individuals having a contraindication for treatment with biguanide compounds, are provided comprising administering delayed release formulations of such biguanide compounds, including metformin, targeted to the small intestine.
    Type: Application
    Filed: January 5, 2013
    Publication date: March 5, 2015
    Inventors: Alain D. Baron, Mark S. Fineman, Niger R.A. Beeley
  • Publication number: 20150064223
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: July 11, 2012
    Publication date: March 5, 2015
    Applicant: Elcelyx Therapeutics, Inc.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R.A. Beeley
  • Publication number: 20150050335
    Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.
    Type: Application
    Filed: February 28, 2013
    Publication date: February 19, 2015
    Inventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
  • Patent number: 8956629
    Abstract: Disclosed is a dental composition, comprising unsaturated double bond-containing monomers and/or oligomers, a catalytic amount of polymerization initiator to initiate polymerization, and a filler, wherein the dental composition comprises an organic nanotube containing an antibacterial or anticariogenic material to inhibit or prevent tooth decay. The dental composition comprises an organic nanotube containing an antibacterial or anticariogenic material, thus uniformly and continuously exhibiting anticariogenic and antibacterial activities, while avoiding deterioration in physical properties required for the dental material.
    Type: Grant
    Filed: May 19, 2008
    Date of Patent: February 17, 2015
    Assignee: Vericom Co. Ltd
    Inventors: Myung-Hwan Oh, Won-Ho Kim, Mi Hyoun Ham, Jong-Hwi Lee, Yun-Ki Kim
  • Patent number: 8952068
    Abstract: The invention relates to the compositions of formula I or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: February 10, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150038589
    Abstract: The present invention relates to a nutritional product comprising a biguanide in a concentration of 20 to 1600 mg per 100 g, based on total weight of the nutritional product, the nutritional product further comprising at least one dietary component selected from the group of (i) digestible carbohydrates, (ii) amino acid sources, such as proteins, peptides, free amino acids including salts of free amino acids, (iii) lipids, and (iv) dietary fibre. The invention further relates to a nutritional product comprising a biguanide for use in a prophylactic or therapeutic treatment of an aging-associated disorder.
    Type: Application
    Filed: July 22, 2011
    Publication date: February 5, 2015
    Inventor: Karel Paul Bouter
  • Publication number: 20150038441
    Abstract: The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of otitis externa, application and dosage information, cannules, cotton swabs, gauzes and information about the cleaning and maintenance ears of a companion animal.
    Type: Application
    Filed: December 21, 2011
    Publication date: February 5, 2015
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Joachim Karle, Reinhard Seffner
  • Publication number: 20150031772
    Abstract: A coating comprised of a polymeric material and a bioactive agent where the properties of the casting solvent dictate the dispersion of the embedding bioactive agent. In preferred embodiments, controlled release of the bioactive agent is achieved by homogeneous dispersion of the bioactive agent within the coating. A further aspect of the invention is directed to formulations where the heterogeneous dispersion of the bioactive agent provides an initial rapid release of the bioactive agent. Methodology for production of coating formulations of the desired properties and the application of the coating to an article are also described.
    Type: Application
    Filed: February 19, 2013
    Publication date: January 29, 2015
    Inventors: Mark Schallenberger, Ben Luchsinger, Todd Meyer, Helena Lovick
  • Publication number: 20150030675
    Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.
    Type: Application
    Filed: April 25, 2014
    Publication date: January 29, 2015
    Applicant: Valeant International Bermuda
    Inventors: Fang ZHOU, Paul MAES
  • Publication number: 20150024021
    Abstract: A method for treating a periodontal disease affecting a periodontal pocket of a patient. The method comprises inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid unit dosage form suitable for insertion into a periodontal pocket of a patient, comprising a therapeutically effective amount of at least one anti-inflammatory agent, at least one antibacterial agent, or the combination of at least one anti-inflammatory agent and at least one antibacterial agent.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 22, 2015
    Inventors: Avi Avramoff, Eyal Shoshani, Adel Penhasi, Dan Oren
  • Publication number: 20150018297
    Abstract: The present disclosure relates to a pharmaceutical composition, a health functional food composition, and a method for preventing or treating a brain disease or diabetes. The pharmaceutical composition, health functional food composition, and method includes at least one active ingredient that is chlorhexidine, thioguanosine, mebendazole, fenbendazole, colchicine, farnesol, trimethobenzamide hydrochloride, disulfuram, azathioprine, mebeverine hydrochloride, zaprinast, tosufloxacin hydrochloride, efavirenz, thiostrepton, probenecid, entacapone, harmine hydrochloride, flunisolide, thimerosal, hexestrol, sulfaquinoxaline sodium salt, monensin sodium salt, raloxifene hydrochloride, 2-chloropyrazine, or topotecan.
    Type: Application
    Filed: July 14, 2014
    Publication date: January 15, 2015
    Applicant: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
    Inventors: Dong Gyu JO, Jong Sung PARK, Youngkwang YOUN, Yuri CHOI, Ui Jeong YUN
  • Publication number: 20150017213
    Abstract: An ocular composition consisting essentially of purified water, PEG-80 sorbitan laurate, sodium trideceth sulfate, PEG-150 distearate, sodium lauroamphoacetate, cocamidopropyl hydroxysultaine, sodium laureth-13 carboxylate, sodium chloride, PEG-15 cocopolyamine, polyhexamethylene biguanide, potassium sorbate, 1,2 hexanediol, and caprylyl glycol. The composition can be applied to a fabric pad for use as an eyelid cleanser, where the fabric pad is pre-moistened with the composition and packaged for use. The composition may also be used in an eyelid treatment kit for convenient combination treatments to improve overall eyelid hygiene and adjunctive eyelid therapy.
    Type: Application
    Filed: July 12, 2013
    Publication date: January 15, 2015
    Inventors: Nat Adkins, JR., Cynthia Barratt
  • Patent number: 8933055
    Abstract: The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. These formulations have a high cidal activity in a short amount of time and provide stable copious foam. The formulations of the present invention also exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: January 13, 2015
    Assignee: Ecolab USA Inc.
    Inventors: Daniel E. Pedersen, Angela R. Eder, Charles A. Hodge
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Publication number: 20150004102
    Abstract: The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, said nanoparticles being based on a vegetable hydrophobic protein, particularly zein, and a water miscible non-volatile organic solvent, particularly propylene glycol. Said nanoparticles can encapsulate or incorporate a product of interest for use in the agricultural, cosmetic, food or pharmaceutical fields.
    Type: Application
    Filed: February 12, 2013
    Publication date: January 1, 2015
    Applicant: BIONANOPLUS, S.L.
    Inventors: Hesham H.A. Salman, Izaskun Goñi Azcárate, Irene Esparza Catalán
  • Patent number: 8921427
    Abstract: An antiseptic preparation is provided for the production of wound dressings or bandages. The preparation includes at least one alginate and at least one antiseptically active substance selected from the group biguanide derivatives, octenidine and taurolidine. Processes for the production of the antiseptic preparations, and the use thereof, are also provided.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: December 30, 2014
    Assignee: Lohmann & Rauscher GmbH & Co. KG
    Inventors: Christian Rohrer, Helmut Leuprecht, Corneliu Iulian Alupei
  • Patent number: 8920837
    Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.
    Type: Grant
    Filed: July 3, 2006
    Date of Patent: December 30, 2014
    Assignee: Rubicon Research Private Limited
    Inventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anilkumar S. Gandhi, Paras R. Jain, Atul A. Kelkar
  • Patent number: 8906364
    Abstract: The present invention provides compositions for preventing growth and proliferation of biofilm embedded microorganisms on devices comprising: (a) a cationic polypeptide and (b) a bis-guanide or a salt thereof. The invention further provides methods for preparing medical devices with such compositions.
    Type: Grant
    Filed: January 11, 2006
    Date of Patent: December 9, 2014
    Assignee: Kane Biotech Inc.
    Inventor: Srinivasa Madhyastha
  • Publication number: 20140348944
    Abstract: This invention relates to a “high lower alcohol content”(>40% v/v of a C1-4 alcohol) liquid composition able to be dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a silicone-based surfactant of at least 0.001% by weight to prepare a foamable composition, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition), and the balance being purified water. The compositions may include emulsifier-emollients and moisturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.
    Type: Application
    Filed: February 24, 2014
    Publication date: November 27, 2014
    Applicant: Deb Worldwide Healthcare Inc.
    Inventors: Maria Teresa Fernandez de Castro, Bruce Michael Koivisto, Francisco Munoz
  • Patent number: 8895621
    Abstract: Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediaminetetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 25, 2014
    Assignee: The University of British Columbia
    Inventor: Markus Haapasalo
  • Patent number: 8895047
    Abstract: Implantable catheters are provided which comprise an antimicrobial agent incorporated in a coating or bulk distributed, in combination with a fibrinolytic agent incorporated in a top coating.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: November 25, 2014
    Assignee: Arrow International, Inc.
    Inventors: Nisha Gupta, Joel Rosenblatt, Daniel J. Spangler